A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 11
- 主要终点
- T-cell responses to GEN-009 adjuvanted vaccine
研究概览
简要总结
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A proprietary tool developed by Genocea, called ATLAS™ (Antigen Lead Acquisition System) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T cells. ATLAS-identified neoantigens will then be incorporated into a patient's personalized vaccine in the form of synthetic long peptides (SLPs).
详细描述
This first-in-human study of GEN-009 will be conducted in two parts in adult patients with cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, or renal cell carcinoma (Part B only). In Part A, the safety and immunogenicity of single-agent GEN-009 will be evaluated in patients with the above-noted tumor types who have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy) and have no evidence of disease (NED) at the time of initiating vaccination with GEN-009. In Part B, up to 15 patients in each disease cohort will be enrolled and evaluated for safety, immunogenicity, and preliminary antitumor activity of GEN-009. Patients in Part B will receive GEN-009 at the schedule selected in Part A, in combination with a PD-1 inhibitor therapy (nivolumab or pembrolizumab) at the approved dose and schedule per the United States Package Insert (USPI). In addition, up to 15 patients who enroll in one of the Part B disease-specific cohorts but whose disease progresses during the screening period therapy may be enrolled into a separate relapsed/refractory disease cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of 1 of the following tumor types:
- •Melanoma (cutaneous).
- •SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal).
- •Urothelial carcinoma.
- •Renal cell carcinoma (Part B only).
- •Understand the study, be willing to comply with all study procedures and sign the informed consent
- •Adequate tumor tissue available
- •ECOG performance status of 0 or 1
- •Negative pregnancy test (females of childbearing potential)
- •Agree to use of contraception during the study until at least 90 days after final GEN-009 dose
- •Adequate hematologic, liver, and kidney function
- •Part A-specific Inclusion:
- •Have completed or will complete treatment for their disease with curative intent
- •Have no evidence of disease
- •Part B-specific Inclusion:
- •Receiving or will initiate treatment with nivolumab or pembrolizumab per disease as listed below:
- •NSCLC: Patients with metastatic non-squamous NSCLC beginning first-line pembrolizumab in combination with pemetrexed and platinum chemotherapy, or metastatic squamous NSCLC beginning first-line pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel
- •SCCHN: Patients beginning pembrolizumab with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy, or beginning first-line pembrolizumab for recurrent or metastatic SCCHN if tumors express PD-L1 with a Combined Positive Score (CPS) ≥
- •Cutaneous Melanoma: Patients with unresectable or metastatic cutaneous melanoma beginning nivolumab monotherapy or nivolumab in combination with ipilimumab.
- •Urothelial Carcinoma: Patients with locally advanced or metastatic urothelial carcinoma who are beginning pembrolizumab who:
- •Are not eligible for cisplatin-containing chemotherapy, and tumor is PD-L1 positive with CPS ≥ 10, or are not eligible for any platinum-containing chemotherapy, OR
- •Have had disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- •Renal Cell Carcinoma:
- •Patients with advanced RCC who have received prior anti-angiogenic therapy, and are beginning nivolumab monotherapy, OR
- •Untreated patients with intermediate or poor risk RCC based on the IMDC score who are beginning nivolumab in combination with ipilimumab.
- •Disease assessment by CT or MRI
- •Have at least 1 lesion that is measureable by RECIST 1.1
- •Agree to a tumor biopsy 50 days after first GEN-009 vaccination
- •Participants with hypothyroidism must be on thyroid replacement treatment
排除标准
- •Received a live vaccine ≤ 28 days, or a non-live vaccine ≤ 14 days, prior to the first dose of GEN-009
- •Acute or chronic skin disorders that would interfere with injection
- •Receiving immunosuppressive therapies or systemic corticosteroids. Note: Use of topical corticosteroids or inhaled corticosteroids is acceptable
- •Allergy to the vaccine adjuvant Hiltonol (poly-ICLC)
- •Active hepatitis B or hepatitis C infection
- •HIV Positive
- •History of clinically significant cardiac condition
- •History of leptomeningeal carcinomatosis
- •Had clinically active immune-mediated disease within 5 years
- •Received a prior allogeneic stem cell transplant
- •Has primary immune deficiency
- •Received a prior solid organ transplant
- •Has malignant disease, other than the tumor types being treated in this study
- •Female patient who is pregnant, breastfeeding, or who plans to become pregnant from the signing of the informed consent until ≥ 90 days from last dose of GEN-009
- •Any condition that in the judgment of the PI would make the patient inappropriate for enrollment in the study
- •Patient has received cytotoxic chemotherapy within 4 weeks of the first leukapheresis
- •Part A-specific Exclusion Criteria:
- •Has received or requires more than 2 adjuvant or neoadjuvant regimens (other than surgical excisions) given with curative intent prior to first GEN-009 vaccination
- •Has not recovered or stabilized from any clinically significant toxicity associated with any prior procedure or anticancer therapy
研究组 & 干预措施
Part A
Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).
Part A will consist of approximately 9 participants.
干预措施: GEN-009 Adjuvanted Vaccine (Biological)
Part B
Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).
Part B will consist of up to 90 participants.
干预措施: GEN-009 Adjuvanted Vaccine (Biological)
Part B
Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).
Part B will consist of up to 90 participants.
干预措施: Nivolumab (Drug)
Part B
Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).
Part B will consist of up to 90 participants.
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
T-cell responses to GEN-009 adjuvanted vaccine
时间窗: 1.5 years after first GEN-009 vaccination
Immunogenicity based on T-cell responses to GEN-009
Incidence of Treatment-Emergent Adverse Events
时间窗: 1.5 years after first GEN-009 vaccination
Adverse events will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
次要结局
- Antitumor activity of GEN-009 in Part B(48 weeks after first GEN-009 vaccination)